Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s97100
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited